This startup is working its business plan well. The FDA problem was due to a myriad of things, most by the FDA not the device and management is to be commended for reaching closure as they did. The secondary offering went well and was forecast well in advance for all those that follow the company ie; due delligence. The additional board members will atract a good sales team going forward and I believe they will be showing revenues by the 2nd quarter of 2012 if not sooner. This will IMO result in a conservative stock price north of $16. It has been fun albeit a little expensive watching the shorts, bashers, wannabes,etc. having fun with Mela over the past year or so. This is a startup that is now ready to perform, has is ducks all in a row and about ready to execute. Going forward follow the facts not the noise and if you know how business works you will be rewarded, handsomely.